论文部分内容阅读
目的探讨人乳头状瘤病毒(HPV)检测在中晚期宫颈癌患者同步放-化疗疗效评估中的意义。方法同步行体外、腔内照射和顺铂化疗的中晚期宫颈癌患者86例,治疗前及治疗后6个月时取宫颈管分泌物以核酸分子快速杂交法检测13种HPV基因型的HPV DNA变化,评估疗效。结果 84例完成随访6个月以上,HPV DNA总阳性率19.05%,高危型HPV DNA阳性率16.67%,均明显低于治疗前的94.19%和89.53%(P<0.05)。治疗后6个月时疗效评定治疗总有效率为80.95%。结论在中晚期宫颈癌同步放-化疗期间,检测HPV感染的变化有助于疗效评估。
Objective To investigate the significance of human papillomavirus (HPV) detection in evaluating the efficacy of concurrent radiotherapy and chemotherapy in patients with advanced cervical cancer. METHODS: Eighty-six patients with advanced cervical cancer who underwent endovascular and cisplatin chemotherapeutics in vitro and in vivo were treated with HPV DNA of 13 HPV genotypes by rapid hybridization with cervical secretions before and 6 months after treatment. Change, evaluate the efficacy. Results 84 cases were followed up for more than 6 months, the total positive rate of HPV DNA was 19.05%, the positive rate of high-risk HPV DNA was 16.67%, which were significantly lower than those of 94.19% and 89.53% before treatment (P <0.05). At 6 months after treatment, the curative effect was evaluated with a total effective rate of 80.95%. Conclusions During the concurrent radiotherapy and chemotherapy of advanced cervical cancer, detecting the change of HPV infection is helpful to evaluate the curative effect.